Table 2: Main characteristics of HCV infection in the 17 SCD patients with positive HCV serology.
| Patient | Age, gender | Positive HCV RNA | HCV genotype | Mode of contamination | Hb level (g/dL) | ALT (IU/L) | Prothrombin time (%) | Liver fibrosis score** | Treatment |
| 1 | 51, M | Y* | 4 | Transfusion | 7 | 157 | 61 | F4 | None |
| 2 | 43, M | Y | 4c | Transfusion | 6.9 | 19 | 7.9 | F3 | None |
| 3 | 44,M | N | ND | NA | 7.2 | 30 | 81 | ND | None |
| 4 | 60,M | N | la | Transfusion | 6.4 | 26 | 61 | F4 | sofosbuvir + daclatasvir |
| 5 | 59, F | N | 4 | Transfusion | 9.0 | 12 | 95 | F0 | Peg IFN + ribavirin |
| 6 | 30, M | N | ND | Transfusion | 9.9 | 31 | 62 | ND | NA |
| 7 | 49, M | N | 1a | Transfusion | 8.7 | 17 | 89 | ND | Peg IFN + ribavirin + telaprevir |
| 8 | 32, M | Y* | 2 | Transfusion | 11.1 | 27 | 92 | F1 | None |
| 9 | 42, M | N | ND | Transfusion | 9.7 | 10 | 73 | ND | None |
| 10 | 46, F | Y | ND | Transfusion | 10.2 | 19 | 85 | F1 | None |
| 11 | 49, F | Y | ND | Transfusion | 9.0 | 43 | NA | ND | None |
| 12 | 34, F | Y* | 1b | Transfusion | 9.2 | 35 | 92 | F3 | None |
| 13 | 35, M | Y | ND | Transfusion | 7.0 | 62 | 97 | F0 | None |
| 14 | 43, F | N | ND | Transfusion | 9.4 | 22 | 90 | F0 | None |
| 15 | 52, F | Y* | 1b | Transfusion | 8.1 | 21 | 92 | F1 | None |
| 16 | 41, F | N | ND | Transfusion | 8.0 | 36 | 97 | ND | None |
| 17 | 57, M | Y* | 4 | Transfusion | 8.0 | 28 | 79 | F3 | None |
HCV = hepatitis C virus; M = male; F = female; Y = Yes; N = No; Y* = patients with HCV viremia > 800,000 IU/mL at the last screening; ND = not done; NA = not available; Hb = haemoglobin; ALT = alanine aminotransferase; **Metavir fibrosis score; Peg-IFN = pegylated interferon.